CA2094533C - Hydrocolloid wound gel - Google Patents
Hydrocolloid wound gel Download PDFInfo
- Publication number
- CA2094533C CA2094533C CA002094533A CA2094533A CA2094533C CA 2094533 C CA2094533 C CA 2094533C CA 002094533 A CA002094533 A CA 002094533A CA 2094533 A CA2094533 A CA 2094533A CA 2094533 C CA2094533 C CA 2094533C
- Authority
- CA
- Canada
- Prior art keywords
- weight
- wound
- gel
- hydrocolloid
- pectin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000416 hydrocolloid Substances 0.000 title claims abstract description 25
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 71
- 206010052428 Wound Diseases 0.000 claims abstract description 69
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 42
- 239000000203 mixture Substances 0.000 claims abstract description 25
- 239000001814 pectin Substances 0.000 claims abstract description 19
- 235000010987 pectin Nutrition 0.000 claims abstract description 19
- 229920001277 pectin Polymers 0.000 claims abstract description 19
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000001768 carboxy methyl cellulose Substances 0.000 claims abstract description 15
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims abstract description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 11
- 239000008213 purified water Substances 0.000 claims description 4
- 239000004615 ingredient Substances 0.000 claims description 3
- 239000002831 pharmacologic agent Substances 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000008367 deionised water Substances 0.000 claims 1
- 229910021641 deionized water Inorganic materials 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 210000000416 exudates and transudate Anatomy 0.000 abstract description 10
- 238000000034 method Methods 0.000 abstract description 7
- 235000013772 propylene glycol Nutrition 0.000 abstract 1
- 239000000499 gel Substances 0.000 description 35
- 230000035876 healing Effects 0.000 description 5
- 230000029663 wound healing Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000002657 fibrous material Substances 0.000 description 3
- 230000001338 necrotic effect Effects 0.000 description 3
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000001804 debridement Methods 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229920000153 Povidone-iodine Polymers 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229920000578 graft copolymer Polymers 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229960001621 povidone-iodine Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 229960003600 silver sulfadiazine Drugs 0.000 description 1
- UEJSSZHHYBHCEL-UHFFFAOYSA-N silver(1+) sulfadiazinate Chemical compound [Ag+].C1=CC(N)=CC=C1S(=O)(=O)[N-]C1=NC=CC=N1 UEJSSZHHYBHCEL-UHFFFAOYSA-N 0.000 description 1
- 239000003009 skin protective agent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000000196 viscometry Methods 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/008—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0023—Polysaccharides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Materials Engineering (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dispersion Chemistry (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
- External Artificial Organs (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Abstract
A hydrocolloid wound gel composition useful for cleansing an debriding wounds and having some capacity for absorbing wound exudate and a method of treating wounds comprising applying the hydrocolloid wound gel to a wound.
The composition includes sodium carboxymethyl-cellulose, pectin, propylene glycol and water.
The composition includes sodium carboxymethyl-cellulose, pectin, propylene glycol and water.
Description
This invention relates to a hydrocolloid wound gel. More particularly, this invention relates to a hydrocolloid wound gel useful for cleansing and debriding wounds and having some moisture absorption capacity.
The invention also relates to a method of treating a wound comprising applying the wound gel to a wound. It is particularly useful for the filling of cavity wounds.
It is well known that the cleansing and debriding of wounds and the removal of wound exudates is important to the process of healing of wounds.
Commonly used wound dressings utilize gauze, foams, sponges, cotton wads or other fibrous materials.
Gauze and other fibrous materials absorb fluids by capillary action. However, gauze and other fibrous materials have the disadvantage in that when new tissue is formed, in the process of healing, it engulfs the fibers of these materials and it is torn when the material is removed causing wound injury on removal.
Various other materials have been used, such as gels, hydrogels, granules and pastes to remove TM
exudates from wounds. Scherisorb Gel marketed by Smith & Nephew containing propylene glycol and a starch-acrylamide t-graft co-polymer has been used as an interactive wound treatment.
The present invention provides a hydrocolloid wound gel composition which cleanses and debrides wounds and has some exudate absorption capacity. The wound gel promotes healing of wounds. The hydrocolloid wound gel contains from about 0.05 to 1.0o by weight of pectin, from about 2.0~ to 4.50 sodium carboxymethylcellulose, from about 15.0 to 20.0 by weight of propylene glycol and the remainder water to make 1000 by weight.
The invention is also directed to a method of wound healing which comprises placing~the hydrocolloid wound gel into the wound to cleanse, debride the wound and absorb exudate to promote wound healing.
The hydrocolloid wound gel keeps the wound bed moist and produces a wound environment suitable for healing. The gel cleanses the wound, debrides necrotic matter from the wound, absorbs exudate without dessiccating or dehydrating the wound bed and promotes wound healing. Freshly generated tissue does not grow into the gel causing injury on removal.
The hydrocolloid wound gel of this invention is particularly useful for chronic cavity type wounds and for wounds containing sloughy or necrotic material The hydrocolloid wound gel composition of the present invention contains from about 0.05 to 1.0~
by weight of pectin, from about 2.0o to 4.5~ by weight of sodium carboxymethylcellulose, from about 15.0% to 20.0 by weight of propylene glycol and the remainder water to make 100%.
The most preferred hydrocolloid wound gel contains 0.1% pectin, 3.4% sodium carboxymethyl cellulose, 15% propylene glycol and 81.5% water.
The pectin is present. in the gel composition in an amount of 0.05% to 1.0% by weight and preferably 0.1%. The preferred pectin is a high ester pectin derived from citrus peel consisting chiefly of the partial methyl esters of polygalacturonic acid (approximately 65% of the carboxyl groups are esterfied). Representative of the pectin useful in the gel composition is that marketed under the name GENU pectin type VIS-L by Copenhagen Pectin.
The gel composition contains sodium carboxymethylcellulose in the amount of 2.0% to 4.5%
by weight and preferably 3.4%. The preferred sodium carboxymethylcellulose is a high viscosity sodium carboxymethylcellulose (typically in the range 2000-4500 CPS as measured by Brookefield LV Viscometry of a 1% solution, oven dry basis, 25°C (spindle 4/30 rpm).
Propylene glycol is present in the amount of 15.0% to 20.0% by weight and preferably 15%.
The water used in the present invention is preferably purified and pyrogen free water and is present in an amount sufficient to bring the composition up to 100% weight and in the preferred composition constitutes 81.5% by weight.
Various optional ingredients can also be included in the final composition such as preservatives, e.g., methylhydroxybenzoate and propylhydroxybenzoate. In addition, the hydrocolloid wound gel composition can, if desired, contain small amounts (effective amount), i.e.. less than 5~, of pharmacologically active ingredients. Fox example, an antibiotic or antimicrobial agent such as metronidazole, silver sulfadiazine, neomycin or penicillin, an antiseptic agent such as povidone iodine, an anti-inflammatory agent such as hydrocortisone or triamcinoloone acetonide, or a skin protective agent such as zinc oxide can be included in the composition.
The hydrocolloid wound gel of this invention is prepared by mixing pectin in water with heating (for example at a temperature from about 50° to 60°C) to form a solution. Propylene glycol is added while mixing and sodium carboxymethylcellulose gradually added with constant mixing to form the gel.
The composition may be packaged in conventional containers, for example, squeeze tube containers or jars and sterilized by wet heat.
The following examples are intended to illustrate the invention described herein without unduly restricting it.
~~~~~c A gel composition was prepared having the following composition:
by Weiaht weiaht Pectin 0.10 0.2 g Sodium Carboxymethyl-cellulose 3.4~ 6.8 g Propylene glycol 15.0 30.0 g Purified Water 81.5 163.0 g Pectin (0.2 g) was added to purified water (163.0 g) in a beaker heated to 50-60°C with constant stirring until the pectin was dissolved. Propylene glycol (30.0 g) was added and sodium carboxymethylcellulose (6.8 g) was gradually added with constant mixing. A hydrocolloid gel (200 g) was produced.
The gel was packaged in epoxy lined aluminum tubes sealed and terminally sterilized by wet heat at 121°C for 30 minutes. The gel when applied to a wound or body surface has good cohesive properties and remains in situ.
Examples 2 -3 Following the procedure described in Example 1, and using the following compositions:
Example 2 Example 3 Weight ~ eig~
Pectin 0.7~ 0.9~
Sodium Carboxymethyl-cellulose 4.0~ 2.5~
Propylene glycol 20.0o 17.0 Purified Water 75.30 79.6 gel compositions are prepared which are useful for treating wounds.
The hydrocolloid wound gel of the present invention cleanses and debrides wounds and absorbs large quantities of wound exudate. The gel enhances wound healing. The main application of the gel is directed to chronic necrotic or sloughy wounds, with large cavities, where debridement absorption and filling are indicated. The wound gel is also useful in treatment of ulcers, burns, pressure sores, etc.
The hydrocolloid wound gel is applied to the wound generally from a tube to cleanse and debride wounds, absorb wound exudate and to enhance healing.
Usually the wound cavity is partially filled with the gel and the wound sealed with an occlusive dressing.
As exudate is generated, it is absorbed by the gel/dressing combination which swells to fill the entire wound cavity. Usually, the hydrocolloid wound gel will not be required to be replaced for several days.
Thus it is apparent from the foregoing description that the objects of this invention have been attained. A novel hydrocolloid wound gel has been invented which has some exudate absorbing capacity, debridement activity and promotes wound healing. In addition, a novel method of treating wounds has been invented.
While this invention has been described and exemplified in terms of its preferred embodiment, those skilled in the art will appreciate that modifications can be made without departing from the spirit and scope of this invention.
The invention also relates to a method of treating a wound comprising applying the wound gel to a wound. It is particularly useful for the filling of cavity wounds.
It is well known that the cleansing and debriding of wounds and the removal of wound exudates is important to the process of healing of wounds.
Commonly used wound dressings utilize gauze, foams, sponges, cotton wads or other fibrous materials.
Gauze and other fibrous materials absorb fluids by capillary action. However, gauze and other fibrous materials have the disadvantage in that when new tissue is formed, in the process of healing, it engulfs the fibers of these materials and it is torn when the material is removed causing wound injury on removal.
Various other materials have been used, such as gels, hydrogels, granules and pastes to remove TM
exudates from wounds. Scherisorb Gel marketed by Smith & Nephew containing propylene glycol and a starch-acrylamide t-graft co-polymer has been used as an interactive wound treatment.
The present invention provides a hydrocolloid wound gel composition which cleanses and debrides wounds and has some exudate absorption capacity. The wound gel promotes healing of wounds. The hydrocolloid wound gel contains from about 0.05 to 1.0o by weight of pectin, from about 2.0~ to 4.50 sodium carboxymethylcellulose, from about 15.0 to 20.0 by weight of propylene glycol and the remainder water to make 1000 by weight.
The invention is also directed to a method of wound healing which comprises placing~the hydrocolloid wound gel into the wound to cleanse, debride the wound and absorb exudate to promote wound healing.
The hydrocolloid wound gel keeps the wound bed moist and produces a wound environment suitable for healing. The gel cleanses the wound, debrides necrotic matter from the wound, absorbs exudate without dessiccating or dehydrating the wound bed and promotes wound healing. Freshly generated tissue does not grow into the gel causing injury on removal.
The hydrocolloid wound gel of this invention is particularly useful for chronic cavity type wounds and for wounds containing sloughy or necrotic material The hydrocolloid wound gel composition of the present invention contains from about 0.05 to 1.0~
by weight of pectin, from about 2.0o to 4.5~ by weight of sodium carboxymethylcellulose, from about 15.0% to 20.0 by weight of propylene glycol and the remainder water to make 100%.
The most preferred hydrocolloid wound gel contains 0.1% pectin, 3.4% sodium carboxymethyl cellulose, 15% propylene glycol and 81.5% water.
The pectin is present. in the gel composition in an amount of 0.05% to 1.0% by weight and preferably 0.1%. The preferred pectin is a high ester pectin derived from citrus peel consisting chiefly of the partial methyl esters of polygalacturonic acid (approximately 65% of the carboxyl groups are esterfied). Representative of the pectin useful in the gel composition is that marketed under the name GENU pectin type VIS-L by Copenhagen Pectin.
The gel composition contains sodium carboxymethylcellulose in the amount of 2.0% to 4.5%
by weight and preferably 3.4%. The preferred sodium carboxymethylcellulose is a high viscosity sodium carboxymethylcellulose (typically in the range 2000-4500 CPS as measured by Brookefield LV Viscometry of a 1% solution, oven dry basis, 25°C (spindle 4/30 rpm).
Propylene glycol is present in the amount of 15.0% to 20.0% by weight and preferably 15%.
The water used in the present invention is preferably purified and pyrogen free water and is present in an amount sufficient to bring the composition up to 100% weight and in the preferred composition constitutes 81.5% by weight.
Various optional ingredients can also be included in the final composition such as preservatives, e.g., methylhydroxybenzoate and propylhydroxybenzoate. In addition, the hydrocolloid wound gel composition can, if desired, contain small amounts (effective amount), i.e.. less than 5~, of pharmacologically active ingredients. Fox example, an antibiotic or antimicrobial agent such as metronidazole, silver sulfadiazine, neomycin or penicillin, an antiseptic agent such as povidone iodine, an anti-inflammatory agent such as hydrocortisone or triamcinoloone acetonide, or a skin protective agent such as zinc oxide can be included in the composition.
The hydrocolloid wound gel of this invention is prepared by mixing pectin in water with heating (for example at a temperature from about 50° to 60°C) to form a solution. Propylene glycol is added while mixing and sodium carboxymethylcellulose gradually added with constant mixing to form the gel.
The composition may be packaged in conventional containers, for example, squeeze tube containers or jars and sterilized by wet heat.
The following examples are intended to illustrate the invention described herein without unduly restricting it.
~~~~~c A gel composition was prepared having the following composition:
by Weiaht weiaht Pectin 0.10 0.2 g Sodium Carboxymethyl-cellulose 3.4~ 6.8 g Propylene glycol 15.0 30.0 g Purified Water 81.5 163.0 g Pectin (0.2 g) was added to purified water (163.0 g) in a beaker heated to 50-60°C with constant stirring until the pectin was dissolved. Propylene glycol (30.0 g) was added and sodium carboxymethylcellulose (6.8 g) was gradually added with constant mixing. A hydrocolloid gel (200 g) was produced.
The gel was packaged in epoxy lined aluminum tubes sealed and terminally sterilized by wet heat at 121°C for 30 minutes. The gel when applied to a wound or body surface has good cohesive properties and remains in situ.
Examples 2 -3 Following the procedure described in Example 1, and using the following compositions:
Example 2 Example 3 Weight ~ eig~
Pectin 0.7~ 0.9~
Sodium Carboxymethyl-cellulose 4.0~ 2.5~
Propylene glycol 20.0o 17.0 Purified Water 75.30 79.6 gel compositions are prepared which are useful for treating wounds.
The hydrocolloid wound gel of the present invention cleanses and debrides wounds and absorbs large quantities of wound exudate. The gel enhances wound healing. The main application of the gel is directed to chronic necrotic or sloughy wounds, with large cavities, where debridement absorption and filling are indicated. The wound gel is also useful in treatment of ulcers, burns, pressure sores, etc.
The hydrocolloid wound gel is applied to the wound generally from a tube to cleanse and debride wounds, absorb wound exudate and to enhance healing.
Usually the wound cavity is partially filled with the gel and the wound sealed with an occlusive dressing.
As exudate is generated, it is absorbed by the gel/dressing combination which swells to fill the entire wound cavity. Usually, the hydrocolloid wound gel will not be required to be replaced for several days.
Thus it is apparent from the foregoing description that the objects of this invention have been attained. A novel hydrocolloid wound gel has been invented which has some exudate absorbing capacity, debridement activity and promotes wound healing. In addition, a novel method of treating wounds has been invented.
While this invention has been described and exemplified in terms of its preferred embodiment, those skilled in the art will appreciate that modifications can be made without departing from the spirit and scope of this invention.
Claims (8)
1. A hydrocolloid wound gel composition which comprises:
(a) from about 0.05 to 1.0% by weight of a pectin;
(b) from about 2.0% to 4.5% by weight of sodium carboxymethylcellulose;
(c) from about 15.0% to 20.0% by weight of propylene glycol; and (d) water in a sufficient amount to make up the difference between the amount of ingredients (a) - (c) and 100% by weight.
(a) from about 0.05 to 1.0% by weight of a pectin;
(b) from about 2.0% to 4.5% by weight of sodium carboxymethylcellulose;
(c) from about 15.0% to 20.0% by weight of propylene glycol; and (d) water in a sufficient amount to make up the difference between the amount of ingredients (a) - (c) and 100% by weight.
2. The hydrocolloid wound gel of claim 1 wherein said wound gel composition comprises:
(a) about 3.4% by weight of sodium carboxy-methylcellulose;
(b) about 0.1% by weight of pectin;
(c) about 15.0% by weight of propylene glycol;
and (d) about 81.5% by weight of purified water.
(a) about 3.4% by weight of sodium carboxy-methylcellulose;
(b) about 0.1% by weight of pectin;
(c) about 15.0% by weight of propylene glycol;
and (d) about 81.5% by weight of purified water.
3. The hydrocolloid wound gel of claim 1 wherein said wound gel composition contains an effective amount of a pharmacologically active ingredient.
4. Use of a hydrocolloid wound gel composition comprising:
(a) from about 0.05% to 1.0% by weight of pectin;
(b) from about 2.0% to 4.5% by weight of sodium carboxymethylcellulose (c) from about 15.0% to 20.0% by weight of propylene glycol; and (d) water in an amount to make up the difference between the amount of ingredients (a)-(c) and 100% by weight for topical treatment of a wound.
(a) from about 0.05% to 1.0% by weight of pectin;
(b) from about 2.0% to 4.5% by weight of sodium carboxymethylcellulose (c) from about 15.0% to 20.0% by weight of propylene glycol; and (d) water in an amount to make up the difference between the amount of ingredients (a)-(c) and 100% by weight for topical treatment of a wound.
5. The use according to claim 4 wherein the hydrocolloid wound gel composition comprises:
(a) about 0.1% by weight of pectin;
(b) about 3.4% by weight of sodium carboxymethylcellulose;
(c) about 15% by weight of propylene glycol;
and (d) about 81.5% by weight of deionized water.
(a) about 0.1% by weight of pectin;
(b) about 3.4% by weight of sodium carboxymethylcellulose;
(c) about 15% by weight of propylene glycol;
and (d) about 81.5% by weight of deionized water.
6. The use according to claim 4 wherein the hydrocolloid wound gel composition contains an effective amount of a pharmaceutically active ingredient.
7. The gel composition of claim 1, 2 or 3 for use in the treatment of wounds.
8. Use of the gel composition of claim 1, 2 or 3 for the manufacture of a medicament for the treatment of wounds.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9208731 | 1992-04-22 | ||
| GB929208731A GB9208731D0 (en) | 1992-04-22 | 1992-04-22 | Hydrocolloid wound gel |
| US08/047,319 US5503847A (en) | 1992-04-22 | 1993-04-15 | Hydrocolloid wound gel |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2094533A1 CA2094533A1 (en) | 1993-10-23 |
| CA2094533C true CA2094533C (en) | 2002-12-10 |
Family
ID=26300763
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002094533A Expired - Lifetime CA2094533C (en) | 1992-04-22 | 1993-04-21 | Hydrocolloid wound gel |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US5503847A (en) |
| EP (1) | EP0567311B1 (en) |
| JP (1) | JP3485593B2 (en) |
| AT (1) | ATE171866T1 (en) |
| AU (1) | AU665996B2 (en) |
| CA (1) | CA2094533C (en) |
| DE (1) | DE69321389T2 (en) |
| DK (1) | DK0567311T3 (en) |
| ES (1) | ES2123619T3 (en) |
| GB (1) | GB9208731D0 (en) |
| NO (1) | NO304773B1 (en) |
| NZ (2) | NZ247431A (en) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9105995D0 (en) * | 1991-03-21 | 1991-05-08 | Smith & Nephew | Wound dressing |
| GB2276819B (en) * | 1993-03-23 | 1996-12-11 | Johnson & Johnson Medical | Aqueous wound treatment composition comprising a polysaccharide and hexylene glycol |
| GB9401279D0 (en) * | 1994-01-24 | 1994-03-23 | Bristol Myers Squibb Co | Wound dressing |
| US5905092A (en) * | 1994-09-27 | 1999-05-18 | Virotex Corporation Reel/Frame | Topical antibiotic composition providing optimal moisture environment for rapid wound healing that reduces skin contraction |
| ES2221931T3 (en) * | 1994-10-28 | 2005-01-16 | Advanced Medical Solutions Limited | DEHYDRATED HYDROGELS. |
| JPH11509442A (en) * | 1995-07-19 | 1999-08-24 | イノベイティブ・テクノロジーズ・リミテッド | Wound treatment composition |
| ATE264119T1 (en) | 1996-07-11 | 2004-04-15 | Coloplast As | HYDROCOLLOID WOUND GEL |
| GB2322864A (en) | 1997-03-07 | 1998-09-09 | Polybiomed Ltd | Gel for application to the human or animal body |
| AU8588898A (en) | 1997-07-28 | 1999-02-16 | Mary L. Redmond | Composition and process for the treatment of epidermal traumas such as decubitusulcers |
| CA2303276A1 (en) | 1997-08-29 | 1999-03-11 | Avery Dennison Corporation | Biological fluid absorbing pressure sensitive adhesives |
| GB9719711D0 (en) | 1997-09-16 | 1997-11-19 | Avery Dennison Corp | Hydrocolloid pressure sensitive adhesive |
| JP3114016B2 (en) | 1998-05-15 | 2000-12-04 | 株式会社ホギメディカル | Wound hemostatic material having cell adhesion promoting effect |
| US6254294B1 (en) * | 1999-08-09 | 2001-07-03 | Sigrid G. Muhar | Pharmaceutical kit |
| DE19957918A1 (en) * | 1999-11-25 | 2001-06-13 | Ulrich Doht | Disinfectant cleaner for cleaning and care and process for its manufacture |
| JP2002226378A (en) * | 2001-01-30 | 2002-08-14 | Mikasa Seiyaku Co Ltd | Reepithelization promoter |
| WO2004011032A1 (en) * | 2002-07-26 | 2004-02-05 | Mikasa Seiyaku Co., Ltd. | External preparation |
| KR100550807B1 (en) | 2002-10-29 | 2006-02-09 | 주식회사 바이오폴 | Filled Polyurethane Foam Dressing Material and Manufacturing Method Thereof |
| US8062661B2 (en) | 2003-12-11 | 2011-11-22 | Teikoku Pharma Usa, Inc. | Methods and compositions for treating skin wounds |
| WO2005058199A1 (en) * | 2003-12-16 | 2005-06-30 | Avery Dennison Corporation | Electrostatically self-assembled antimicrobial coating for medical applications |
| GB2409974A (en) * | 2004-01-14 | 2005-07-20 | Avanticare Ltd | Gel comprising citrus complex carbohydrates for the application to a wound |
| GB0423485D0 (en) * | 2004-10-22 | 2004-11-24 | First Water Ltd | Absorbent materials and articles |
| US7534837B2 (en) | 2005-09-26 | 2009-05-19 | E.I. Du Pont De Nemours And Company | Random copolymers of ethylene and 4-vinylphenyl esters and method for preparing the same |
| JP5371443B2 (en) | 2005-12-22 | 2013-12-18 | ニューラルタス ファーマシューティカルズ，インコーポレイテッド | Chlorite formulations and methods and uses of this preparation |
| KR100777908B1 (en) * | 2006-12-19 | 2007-11-28 | 주식회사 바이오폴 | Polyurethane foam dressing with improved repair rate |
| JP5582711B2 (en) * | 2008-09-25 | 2014-09-03 | 株式会社エー・アイ・システムプロダクト | Lotion |
| US8741267B1 (en) | 2009-06-26 | 2014-06-03 | Joseph P. Trovato | Method for treating periodontal disease |
| US20120035558A1 (en) * | 2010-08-06 | 2012-02-09 | Popa Peter R | Wound Cleaning Adhesive Patch |
| CN101987207A (en) * | 2010-11-01 | 2011-03-23 | 南京斯瑞奇医疗用品有限公司 | Wound surface dressing soluble colloid and preparation method thereof |
| CN102153784B (en) * | 2011-04-15 | 2012-07-11 | 武汉市思泰利医疗器械发展有限公司 | Amorphous hydrogel and preparation method thereof |
| GB2490516A (en) | 2011-05-03 | 2012-11-07 | Systagenix Wound Man Ip Co Bv | Polysaccharide mould for wound treatment |
| PT2550977T (en) | 2011-07-27 | 2017-08-08 | Genewel Co Ltd | Polyurethane foam dressing having excellent adhesive properties and manufacturing method thereof |
| JP6383721B2 (en) | 2013-02-22 | 2018-08-29 | 三洋化成工業株式会社 | Wound healing agent |
| FR3023166B1 (en) * | 2014-07-07 | 2018-01-12 | Laboratoires Rivadis Sas | USE OF A PHARMACEUTICAL COMPOSITION COMPRISING A PECTIN AS AN ACTIVE INGREDIENT IN THE PREVENTION AND / OR TREATMENT OF SKIN DISEASES INVOLVING INFLAMMATORY CHARACTER |
| CA2963595C (en) | 2014-10-28 | 2023-07-11 | Biovotec As | Micronized eggshell membrane particles and the use thereof to promote the healing of wounds |
| KR102702872B1 (en) | 2015-06-24 | 2024-09-05 | 바이오보텍 에이에스 | Tissue engineering scaffolds containing microparticle shell membrane |
| GB201519923D0 (en) | 2015-11-11 | 2015-12-23 | Biovotec Dac And Biovotec As | Dry biocompatible disintegrateable films for delivering particulate egg shell membrane to a wound |
| WO2018108256A1 (en) * | 2016-12-13 | 2018-06-21 | Stahl Kurt Wilhelm | Composition for dressing cutaneous lesions and manufacturing method thereof |
| GB2572642B (en) * | 2018-04-06 | 2021-03-31 | Pellis Care Ltd | Treatment of diabetic foot ulcers |
| KR102684366B1 (en) | 2018-10-05 | 2024-07-11 | 고쿠리츠다이가쿠호진 히로시마다이가쿠 | Materials for meniscus regeneration |
| CN109772237B (en) * | 2019-01-24 | 2020-06-26 | 厦门大学 | A method for embedding loads based on ultra-high pressure liquefaction of gel |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3640741A (en) * | 1970-02-24 | 1972-02-08 | Hollister Inc | Composition containing gel |
| US4140807A (en) * | 1977-08-29 | 1979-02-20 | Amiel Braverman | Flavored freezable-gel confection |
| US4292972A (en) * | 1980-07-09 | 1981-10-06 | E. R. Squibb & Sons, Inc. | Lyophilized hydrocolloio foam |
| GB8512358D0 (en) * | 1985-05-16 | 1985-06-19 | Euro Celtique Sa | Transdermal delivery system |
| US4813942A (en) * | 1987-03-17 | 1989-03-21 | Bioderm, Inc. | Three step wound treatment method and dressing therefor |
| JPS63313709A (en) * | 1987-06-16 | 1988-12-21 | Lion Corp | Method for producing skin-covering composition |
| FR2638638B1 (en) * | 1988-11-09 | 1993-01-22 | Biotrol Sa Lab | ADHESIVE PASTE FOR PROTECTING THE SKIN, PREPARATION METHOD THEREOF, THERAPEUTIC APPLICATIONS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
| DE3903672C1 (en) * | 1989-02-08 | 1990-02-01 | Lohmann Gmbh & Co Kg | |
| US5395305A (en) * | 1990-08-30 | 1995-03-07 | Terumo Kabushiki Kaisha | Multilayer wound covering materials comprising a supporting layer and a moisture permeation controlling layer and method for their manufacture |
-
1992
- 1992-04-22 GB GB929208731A patent/GB9208731D0/en active Pending
-
1993
- 1993-04-15 US US08/047,319 patent/US5503847A/en not_active Expired - Lifetime
- 1993-04-19 NZ NZ247431A patent/NZ247431A/en not_active IP Right Cessation
- 1993-04-21 NO NO931171A patent/NO304773B1/en not_active IP Right Cessation
- 1993-04-21 AU AU37035/93A patent/AU665996B2/en not_active Expired
- 1993-04-21 EP EP93303090A patent/EP0567311B1/en not_active Expired - Lifetime
- 1993-04-21 CA CA002094533A patent/CA2094533C/en not_active Expired - Lifetime
- 1993-04-21 DK DK93303090T patent/DK0567311T3/en active
- 1993-04-21 AT AT93303090T patent/ATE171866T1/en not_active IP Right Cessation
- 1993-04-21 ES ES93303090T patent/ES2123619T3/en not_active Expired - Lifetime
- 1993-04-21 DE DE69321389T patent/DE69321389T2/en not_active Expired - Lifetime
- 1993-04-22 JP JP09580593A patent/JP3485593B2/en not_active Expired - Lifetime
-
1995
- 1995-09-12 NZ NZ272995A patent/NZ272995A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DE69321389T2 (en) | 1999-03-04 |
| JPH069373A (en) | 1994-01-18 |
| ATE171866T1 (en) | 1998-10-15 |
| EP0567311A2 (en) | 1993-10-27 |
| AU665996B2 (en) | 1996-01-25 |
| DE69321389D1 (en) | 1998-11-12 |
| US5503847A (en) | 1996-04-02 |
| ES2123619T3 (en) | 1999-01-16 |
| GB9208731D0 (en) | 1992-06-10 |
| NZ247431A (en) | 1995-11-27 |
| CA2094533A1 (en) | 1993-10-23 |
| DK0567311T3 (en) | 1999-06-21 |
| NZ272995A (en) | 1997-01-29 |
| JP3485593B2 (en) | 2004-01-13 |
| EP0567311A3 (en) | 1994-08-10 |
| NO304773B1 (en) | 1999-02-15 |
| NO931468D0 (en) | 1993-04-21 |
| EP0567311B1 (en) | 1998-10-07 |
| NO931468L (en) | 1993-10-25 |
| AU3703593A (en) | 1993-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2094533C (en) | Hydrocolloid wound gel | |
| JP2664539B2 (en) | Wound dressing | |
| US5662924A (en) | Wound dressing | |
| JP2617260B2 (en) | Gel composition for wound treatment | |
| JP4514955B2 (en) | Aseptic non-adhesive compressor | |
| US5905092A (en) | Topical antibiotic composition providing optimal moisture environment for rapid wound healing that reduces skin contraction | |
| US7714183B2 (en) | Use of honey in dressings | |
| US5914124A (en) | Alginate fibre, process for the preparation thereof and use | |
| US5441741A (en) | Freeze-dried pad | |
| US5902600A (en) | Hydrogel polymer wound dressing | |
| JPH08187280A (en) | Sterile gel composition for treating wounds and method of making gel | |
| AU2001282707A1 (en) | The use of honey in wound dressings | |
| US8632810B2 (en) | Hydrocolloid composition | |
| EP0666081B1 (en) | Wound dressing | |
| HU201683B (en) | Process for producing pharmaceutical compositions for promoting healing of wounds | |
| WO2003061538A1 (en) | Particulate wound dressings | |
| Bell et al. | Choosing an appropriate dressing for chronic wounds | |
| ALMURAYSHID | AND AFSANEH ALAVI MD, MSC | |
| CN115838518A (en) | A kind of long-term storage hydrogel, preparation method and application | |
| EP0987019A1 (en) | Topical antibiotic composition for rapid wound healing |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20130421 |